Infusion of clinical‐grade enriched regulatory T cells delays experimental xenogeneic graft‐versus‐host disease

We investigated the ability of clinical‐grade enriched human regulatory T cells (Treg) to attenuate experimental xenogeneic graft‐versus‐host disease (GVHD) induced by peripheral blood mononuclear cells (PBMNCs; autologous to Treg) infusion in NSG mice, as well as verified their inability to induce xenogeneic GVHD when infused alone.

[1]  Helen E. Heslop,et al.  Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease , 2013, Haematologica.

[2]  F. Baron,et al.  Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease. , 2013, Cytotherapy.

[3]  Jang-Gi Choi,et al.  Long-Term Engraftment of Human Natural T Regulatory Cells in NOD/SCID IL2rγcnull Mice by Expression of Human IL-2 , 2012, PloS one.

[4]  F. Baron,et al.  Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation , 2012, Leukemia.

[5]  A. Liston,et al.  Immune tolerance: Are regulatory T cell subsets needed to explain suppression of autoimmunity? , 2012, BioEssays : news and reviews in molecular, cellular and developmental biology.

[6]  Bruce R. Blazar,et al.  Advances in graft-versus-host disease biology and therapy , 2012, Nature Reviews Immunology.

[7]  P. Coulie,et al.  Demethylation of the FOXP3 gene in human melanoma cells precludes the use of this epigenetic mark for quantification of Tregs in unseparated melanoma samples , 2012, International journal of cancer.

[8]  Graham M Lord,et al.  A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. , 2012, Blood.

[9]  G. Storm,et al.  Application of cultured human regulatory T cells requires preclinical in vivo evaluation. , 2012, The Journal of allergy and clinical immunology.

[10]  J. Ritz,et al.  Interleukin-2 and regulatory T cells in graft-versus-host disease. , 2011, The New England journal of medicine.

[11]  J. Ritz,et al.  Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. , 2011, Blood.

[12]  B. Storer,et al.  Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. , 2011, Blood.

[13]  M. Edinger,et al.  Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. , 2011, Current opinion in immunology.

[14]  M. Battaglia,et al.  Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells , 2011, Haematologica.

[15]  R. Negrin,et al.  Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. , 2011, Blood.

[16]  F. Baron,et al.  Regulatory T cells fulfil their promise? , 2011, Immunology and cell biology.

[17]  Bruce R. Blazar,et al.  Massive ex Vivo Expansion of Human Natural Regulatory T Cells (Tregs) with Minimal Loss of in Vivo Functional Activity , 2011, Science Translational Medicine.

[18]  B. Falini,et al.  Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. , 2011, Blood.

[19]  S. Ziegler,et al.  Blood and gastric FOXP3+ T cells are not decreased in human gastric graft-versus-host disease. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  R. Storb,et al.  Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age , 2011, Haematologica.

[21]  J. Wagner,et al.  Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. , 2011, Blood.

[22]  R. Porcher,et al.  The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation , 2010, Leukemia.

[23]  J. Ritz,et al.  Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. , 2010, The Journal of clinical investigation.

[24]  T. Braun,et al.  Frequency of CD4 + CD25 hi FOXP3 + Regulatory T Cells Has Diagnostic and Prognostic Value as a Biomarker for Acute Graft-Versus-Host Disease. , 2009 .

[25]  R. Negrin,et al.  Rapamycin and IL-2 Prevents Lethal Acute Graft-Versus Host Disease by Expansion of Donor Type CD4+CD25+Foxp3+ Regulatory T Cells. , 2009 .

[26]  M. Martelli,et al.  Immunomagnetic isolation of CD4+CD25+FoxP3+ natural T regulatory lymphocytes for clinical applications , 2009, Clinical and experimental immunology.

[27]  P. Coulie,et al.  Comparison of stable human Treg and Th clones by transcriptional profiling , 2009, European journal of immunology.

[28]  J. Buckner,et al.  Combination of rapamycin and IL-2 increases de novo induction of human CD4(+)CD25(+)FOXP3(+) T cells. , 2008, Journal of autoimmunity.

[29]  F. Baron,et al.  Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning , 2008, Haematologica.

[30]  J. Dipersio,et al.  Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice. , 2007, Experimental hematology.

[31]  L. Verdonck,et al.  Human Regulatory T Cells Control Xenogeneic Graft-versus-Host Disease Induced by Autologous T Cells in RAG2−/−γc−/− Immunodeficient Mice , 2006, Clinical Cancer Research.

[32]  E. Holler,et al.  Isolation of CD4+CD25+ regulatory T cells for clinical trials. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[33]  E. Thiel,et al.  Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. , 2006, Blood.

[34]  B. Blazar,et al.  Acute graft-versus-host disease: from the bench to the bedside. , 2005, Blood.

[35]  M. Sorror,et al.  Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Storb,et al.  Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review , 2004, Springer Seminars in Immunopathology.

[37]  E. Warren,et al.  The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. , 2003, Blood reviews.

[38]  C. Fathman,et al.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.

[39]  Catherine J. Wu,et al.  Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[40]  Sayuri Yamazaki,et al.  Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance , 2001, Immunological reviews.

[41]  K. Sullivan,et al.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.

[42]  R. Storb,et al.  Infusion of donor lymphocytes into stable canine radiation chimeras: implications for mechanism of transplantation tolerance. , 1976, Journal of immunology.

[43]  R. Negrin,et al.  Natural and expanded CD4(+)CD25(+) regulatory T cells in bone marrow transplantation. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[44]  H. Ochs,et al.  The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 , 2001, Nature Genetics.